title: Effect of an injectable cabergoline formulation on serum prolactin (PRL) and milk secretion in early postpartum Beagle bitches.
abstract: This study was conducted in order to evaluate effects on prolactin (PRL) concentration and mammary milk secretion of an injectable cabergoline formulation administered to five lactating Beagle bitches during early postpartum (PP). Bitches were bled twice daily (from PP day 3 to PP day 12) and then daily (from PP day 13 to PP day 16) to assay serum PRL. On PP day 6, a subcutaneous (SC) injection of 0.1 ml/kg of placebo was administered. On PP day 9, a SC 0.1 ml/kg dose of injectable cabergoline was administered. All bitches were checked for milk production, using a clinical scoring in order to quantify milk expression from each teat. A circadian variation of serum PRL was evident during the 6 days of pre-treatment monitoring. The day after cabergoline injection, an 80% decrease of PRL serum concentration was observed (p < 0.05). The circadian oscillatory pattern of PRL secretion disappeared after administration of cabergoline, and PRL values remained significantly lower than in the previous days for the first 60 h following treatment (p < 0.001). Milk production was drastically reduced when comparing pre-treatment to post-treatment scores (p < 0.001). A single dose of injectable cabergoline caused a significant reduction in serum PRL concentration and a significant reduction in milk flow. The injectable formulation of cabergoline appeared to be safe and well tolerated.
authors.affiliation: Department of Veterinary Clinical Sciences, Faculty of Veterinary Medicine, University of Padova, Padova, Italy. stefano.romagnoli@unipd.it
authors.forename: S
authors.initials: S
authors.lastname: Romagnoli
authors.forename: C
authors.initials: C
authors.lastname: Milani
authors.forename: S
authors.initials: S
authors.lastname: Perin
authors.forename: R
authors.initials: R
authors.lastname: Ballabio
authors.forename: C
authors.initials: C
authors.lastname: Stelletta
authors.forename: A
authors.initials: A
authors.lastname: Mollo
authors.forename: D
authors.initials: D
authors.lastname: Gelli
mesh_terms: D000818:Animals; D000077465:Cabergoline; D004285:Dogs; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D007774:Lactation / Q000187:drug effects*; D049590:Postpartum Period; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*; D013997:Time Factors
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline